[A case of recurrent liposarcoma treated with bevacizumab chemotherapy resulting in prolonged disease-free survival and long-term overall survival].

Abstract

Retroperitoneal dedifferentiated liposarcoma is associated with a poor prognosis, and the efficacy of chemotherapy in such cases is controversial. We report a case of long -term survival in a patient with dedifferentiated liposarcoma treated with bevacizumab after repeated local recurrences. A 65-year-old man complained of abdominal pain. Abdominal computed tomography (CT) showed a well-enhanced retroperitoneal tumor. The tumor was resected together with the right kidney and adrenal gland. On the basis of histopathological findings, the tumor was diagnosed as a dedifferentiated liposarcoma adenocarcinoma. Eleven months later, local recurrence was diagnosed and the tumor was resected. Thereafter, repeated local recurrences were diagnosed, and repeated tumor resections were performed. Local recurrence and distant metastasis in the axilla and scapula soft tissue was detected 5.9 years after the initial operation. Bevacizumab therapy was initiated, and the tumor markedly reduced in size. Bevacizumab treatment has been continued for 6.7 years after the initial operation, with no tumor recurrence or metastasis.

• Authors: Ryushiro Yamaguchi, Yuji Nakagawa, Munekatsu Sato, Atsushi Ono
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 41 Issue 9 Pg. 1183-5 (Sep 2014) ISSN: 0385-0684 [Print] Japan
• PMID: 25248909 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Antibodies, Monoclonal, Humanized
• Bevacizumab

Topics

• Aged
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Bevacizumab
• Combined Modality Therapy
• Disease-Free Survival
• Humans
• Liposarcoma (drug therapy, surgery)
• Male
• Recurrence
• Retroperitoneal Neoplasms (drug therapy, pathology, surgery)
• Time Factors
• Treatment Outcome